S&P 500   5,062.56 (+1.62%)
DOW   38,883.30 (+0.70%)
QQQ   435.61 (+2.35%)
AAPL   182.97 (+0.36%)
MSFT   411.27 (+2.26%)
META   485.56 (+3.75%)
GOOGL   144.23 (+1.18%)
AMZN   172.54 (+2.34%)
TSLA   193.06 (-0.88%)
NVDA   777.30 (+15.20%)
NIO   5.74 (-3.85%)
AMD   180.03 (+9.58%)
BABA   75.54 (-0.05%)
T   16.62 (-2.24%)
F   12.21 (+0.58%)
MU   85.42 (+4.82%)
CGC   3.44 (+0.00%)
GE   151.22 (+1.44%)
DIS   108.01 (+0.32%)
AMC   4.54 (-0.66%)
PFE   27.23 (-1.59%)
PYPL   57.59 (+0.19%)
XOM   104.44 (-0.39%)
S&P 500   5,062.56 (+1.62%)
DOW   38,883.30 (+0.70%)
QQQ   435.61 (+2.35%)
AAPL   182.97 (+0.36%)
MSFT   411.27 (+2.26%)
META   485.56 (+3.75%)
GOOGL   144.23 (+1.18%)
AMZN   172.54 (+2.34%)
TSLA   193.06 (-0.88%)
NVDA   777.30 (+15.20%)
NIO   5.74 (-3.85%)
AMD   180.03 (+9.58%)
BABA   75.54 (-0.05%)
T   16.62 (-2.24%)
F   12.21 (+0.58%)
MU   85.42 (+4.82%)
CGC   3.44 (+0.00%)
GE   151.22 (+1.44%)
DIS   108.01 (+0.32%)
AMC   4.54 (-0.66%)
PFE   27.23 (-1.59%)
PYPL   57.59 (+0.19%)
XOM   104.44 (-0.39%)
S&P 500   5,062.56 (+1.62%)
DOW   38,883.30 (+0.70%)
QQQ   435.61 (+2.35%)
AAPL   182.97 (+0.36%)
MSFT   411.27 (+2.26%)
META   485.56 (+3.75%)
GOOGL   144.23 (+1.18%)
AMZN   172.54 (+2.34%)
TSLA   193.06 (-0.88%)
NVDA   777.30 (+15.20%)
NIO   5.74 (-3.85%)
AMD   180.03 (+9.58%)
BABA   75.54 (-0.05%)
T   16.62 (-2.24%)
F   12.21 (+0.58%)
MU   85.42 (+4.82%)
CGC   3.44 (+0.00%)
GE   151.22 (+1.44%)
DIS   108.01 (+0.32%)
AMC   4.54 (-0.66%)
PFE   27.23 (-1.59%)
PYPL   57.59 (+0.19%)
XOM   104.44 (-0.39%)
S&P 500   5,062.56 (+1.62%)
DOW   38,883.30 (+0.70%)
QQQ   435.61 (+2.35%)
AAPL   182.97 (+0.36%)
MSFT   411.27 (+2.26%)
META   485.56 (+3.75%)
GOOGL   144.23 (+1.18%)
AMZN   172.54 (+2.34%)
TSLA   193.06 (-0.88%)
NVDA   777.30 (+15.20%)
NIO   5.74 (-3.85%)
AMD   180.03 (+9.58%)
BABA   75.54 (-0.05%)
T   16.62 (-2.24%)
F   12.21 (+0.58%)
MU   85.42 (+4.82%)
CGC   3.44 (+0.00%)
GE   151.22 (+1.44%)
DIS   108.01 (+0.32%)
AMC   4.54 (-0.66%)
PFE   27.23 (-1.59%)
PYPL   57.59 (+0.19%)
XOM   104.44 (-0.39%)

20 "Past Their Prime" Stocks to Dump From Your Portfolio

Did you know the S&P 500 as we know it today does not look anything close to what it looked like 30 years ago? In 1987, IBM, Exxon, GE, Shell, AT&T, Merck, Du Pont, Philip Morris, Ford, and GM had the largest market caps on the S&P 500. ExxonMobil is the only company on that list to remain in the top 10 in 2023. Even 15 years ago, companies like Radio Shack, AOL, Yahoo, and Blockbuster were an important part of the S&P 500. Now, these companies no longer exist as public companies.

As the years go by, some companies lose their luster, and others rise to the top of the markets. We've already seen this in the last few decades, with tech companies surpassing industrial and energy companies that once dominated the S&P 500. It's hard to know what the next mega-trend will be that knocks Apple, Google, and Amazon off the top rankings of the S&P 500, but we know that companies don't stay on the S&P 500 forever.

We have identified 20 companies that are past their prime. They aren't at risk of a near-term delisting from the S&P 500, but they show negative earnings growth for the next several years. If you own any of these stocks, consider whether they still belong in your portfolio before they become the next Yahoo, Radio Shack, Blockbuster, AOL and are sold off for a fraction of their former value.

#1 - Frontier Communications Parent (NASDAQ:FYBR)

Frontier Communications Parent logoFrontier Communications Parent, Inc, together with its subsidiaries, provides communication and technology services in the United States. It offers data and Internet, voice, video, and other services. The company was formerly known as Frontier Communications Corporation and changed its name to Frontier Communications Parent, Inc in April 2021. Read More 
 
Trailing Twelve Months EPS: $0.68
2024 EPS Estimate: $0.02
2025 EPS Estimate: ($0.06)

Current Stock Price
$21.45
P/E Ratio
31.5
Consensus Rating
Moderate Buy
Ratings Breakdown
6 Buy Ratings, 2 Hold Ratings, 1 Sell Ratings.
Consensus Price Target
$28.00 (30.5% Upside)



#2 - HUTCHMED (NASDAQ:HCM)

HUTCHMED logoHUTCHMED (China) Limited discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in Hong Kong and internationally. The company develops Savolitinib, an inhibitor for non-small cell lung cancer (NSCLC), papillary and renal cell carcinoma, colorectal cancer (CRC), and gastric cancer (GC); and Fruquintinib, an inhibitor for CRC, breast cancer, GC, endometrial cancer (EMC), NSCLC, hepatocellular carcinoma, and gastrointestinal and solid tumors. Read More 
 
2024 EPS Estimate: $0.09
2025 EPS Estimate: ($0.52)

Current Stock Price
$15.14
Consensus Rating
Moderate Buy
Ratings Breakdown
3 Buy Ratings, 1 Hold Ratings, 0 Sell Ratings.
Consensus Price Target
$29.70 (96.2% Upside)



#3 - Inari Medical (NASDAQ:NARI)

Inari Medical logoInari Medical, Inc builds minimally invasive, novel, and catheter-based mechanical thrombectomy systems for the specific disease states in the United States. The company provides ClotTriever, which is designed to core, capture, and remove large clots from large vessels for treatment of deep vein thrombosis and peripheral thrombus; and FlowTriever, a large bore catheter-based aspiration and mechanical thrombectomy system to remove large clots from large vessels in the peripheral vasculature for treating pulmonary embolism and other complex venous thromboembolism cases. Read More 
 
Trailing Twelve Months EPS: ($0.06)
2024 EPS Estimate: $0.06
2025 EPS Estimate: ($0.10)

Current Stock Price
$56.68
Consensus Rating
Moderate Buy
Ratings Breakdown
5 Buy Ratings, 1 Hold Ratings, 0 Sell Ratings.
Consensus Price Target
$81.29 (43.4% Upside)



#4 - TransMedics Group (NASDAQ:TMDX)

TransMedics Group logoTransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Read More 
 
Trailing Twelve Months EPS: ($1.10)
2024 EPS Estimate: ($0.33)
2025 EPS Estimate: ($0.80)

Current Stock Price
$85.93
Consensus Rating
Moderate Buy
Ratings Breakdown
7 Buy Ratings, 1 Hold Ratings, 0 Sell Ratings.
Consensus Price Target
$83.33 (3.0% Downside)



#5 - Sunrun (NASDAQ:RUN)

Sunrun logoSunrun Inc engages in the design, development, installation, sale, ownership, and maintenance of residential solar energy systems in the United States. It also sells solar energy systems and products, such as panels and racking; and solar leads generated to customers. In addition, the company offers battery storage along with solar energy systems; and sells services to commercial developers through multi-family and new homes. Read More 
 
Trailing Twelve Months EPS: ($5.50)
2024 EPS Estimate: ($0.58)
2025 EPS Estimate: ($1.42)

Current Stock Price
$14.48
Consensus Rating
Moderate Buy
Ratings Breakdown
17 Buy Ratings, 6 Hold Ratings, 0 Sell Ratings.
Consensus Price Target
$25.82 (78.3% Upside)



#6 - Polestar Automotive Holding UK (NASDAQ:PSNY)

Polestar Automotive Holding UK logoPolestar Automotive Holding UK PLC manufactures and sells premium electric vehicles. The company was founded in 2017 and is headquartered in Gothenburg, Sweden.
 
2024 EPS Estimate: ($0.40)
2025 EPS Estimate: ($0.57)

Current Stock Price
$1.43
Consensus Rating
Hold
Ratings Breakdown
4 Buy Ratings, 1 Hold Ratings, 2 Sell Ratings.
Consensus Price Target
$4.53 (216.4% Upside)



#7 - Galapagos (NASDAQ:GLPG)

Galapagos logoGalapagos NV, an integrated biopharmaceutical company, engages in the discovery, development, and commercialization of?various medicines for high unmet medical need. Its pipeline products include filgotinib, a JAK1 inhibitor that is in various phases of clinical trials for the treatment of rheumatoid arthritis, Crohn's disease, ulcerative colitis, ankylosing spondylitis, psoriatic arthritis, and uveitis. Read More 
 
Trailing Twelve Months EPS: ($2.29)
2024 EPS Estimate: ($0.79)
2025 EPS Estimate: ($1.68)

Current Stock Price
$38.84
Consensus Rating
Hold
Ratings Breakdown
1 Buy Ratings, 5 Hold Ratings, 0 Sell Ratings.
Consensus Price Target
$42.33 (9.0% Upside)



#8 - Joby Aviation (NYSE:JOBY)

Joby Aviation logoJoby Aviation, Inc, a vertically integrated air mobility company, engages in building an electric vertical takeoff and landing aircraft optimized to deliver air transportation as a service. The company intends to build an aerial ridesharing service, as well as developing an application-based platform that will enable consumers to book rides. Read More 
 
Trailing Twelve Months EPS: ($0.75)
2024 EPS Estimate: ($0.61)
2025 EPS Estimate: ($0.68)

Current Stock Price
$5.72
Consensus Rating
Hold
Ratings Breakdown
3 Buy Ratings, 0 Hold Ratings, 2 Sell Ratings.
Consensus Price Target
$7.60 (32.9% Upside)



#9 - MoonLake Immunotherapeutics (NASDAQ:MLTX)

MoonLake Immunotherapeutics logoMoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It is developing Sonelokimab, a novel investigational Nanobody for the treatment of inflammation diseases. The company is involved in conducting Phase II trials for hidradenitis suppurativa, psoriatic arthritis, ankylosing spondylitis, or axial spondyloarthritis. Read More 
 
Trailing Twelve Months EPS: ($0.95)
2024 EPS Estimate: ($0.85)
2025 EPS Estimate: ($1.12)

Current Stock Price
$53.81
Consensus Rating
Moderate Buy
Ratings Breakdown
9 Buy Ratings, 2 Hold Ratings, 0 Sell Ratings.
Consensus Price Target
$72.64 (35.0% Upside)



#10 - Immunocore (NASDAQ:IMCR)

Immunocore logoImmunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also developing other programs for oncology comprise tebentafusp that is in Phase 2/3 clinical trial in patients with advanced melanoma; IMC-F106C, which is in a Phase I/II dose escalation trial in patients with multiple solid tumor cancers comprising cutaneous melanoma, ovarian, non-small cell lung cancer, and endometrial; IMC-T119C for multiple solid tumor cancers; IMC-P115C for multiple solid tumor cancers; and IMC-R117C, which is for a range of tumors, including colorectal, gastro-esophageal, and pancreatic cancers. Read More 
 
Trailing Twelve Months EPS: ($1.39)
2024 EPS Estimate: ($0.97)
2025 EPS Estimate: ($1.44)

Current Stock Price
$70.45
Consensus Rating
Moderate Buy
Ratings Breakdown
12 Buy Ratings, 1 Hold Ratings, 0 Sell Ratings.
Consensus Price Target
$75.17 (6.7% Upside)



#11 - CymaBay Therapeutics (NASDAQ:CBAY)

CymaBay Therapeutics logoCymaBay Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. Its lead product candidate is seladelpar (MBX-8025), a selective agonist of peroxisome proliferator activated receptor delta for the treatments of autoimmune liver disease, primary biliary cholangitis (PBC). Read More 
 
Trailing Twelve Months EPS: ($0.92)
2024 EPS Estimate: ($0.95)
2025 EPS Estimate: ($1.34)

Current Stock Price
$32.21
Consensus Rating
Hold
Ratings Breakdown
2 Buy Ratings, 11 Hold Ratings, 0 Sell Ratings.
Consensus Price Target
$26.73 (17.0% Downside)



#12 - CG Oncology (NASDAQ:CGON)

CG Oncology logoCG Oncology is a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. CG Oncology is based in IRVINE, Calif.
 
2024 EPS Estimate: ($1.23)
2025 EPS Estimate: ($2.01)

Current Stock Price
$45.68
Consensus Rating
Moderate Buy
Ratings Breakdown
3 Buy Ratings, 1 Hold Ratings, 0 Sell Ratings.
Consensus Price Target
$61.75 (35.2% Upside)



#13 - QuantumScape (NYSE:QS)

QuantumScape logoQuantumScape Corporation, a development stage company, focuses on the development and commercialization of solid-state lithium-metal batteries for electric vehicles and other applications. QuantumScape Corporation was founded in 2010 and is headquartered in San Jose, California.
 
Trailing Twelve Months EPS: ($0.96)
2024 EPS Estimate: ($0.92)
2025 EPS Estimate: ($1.03)

Current Stock Price
$6.22
Consensus Rating
Reduce
Ratings Breakdown
1 Buy Ratings, 4 Hold Ratings, 3 Sell Ratings.
Consensus Price Target
$6.71 (7.9% Upside)



#14 - Viking Therapeutics (NASDAQ:VKTX)

Viking Therapeutics logoViking Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. Read More 
 
Trailing Twelve Months EPS: ($0.92)
2024 EPS Estimate: ($1.12)
2025 EPS Estimate: ($1.40)

Current Stock Price
$36.25
Consensus Rating
Buy
Ratings Breakdown
8 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings.
Consensus Price Target
$34.00 (6.2% Downside)



#15 - Liberty Live Group (NASDAQ:LLYVK)

Liberty Live Group logoLiberty Live Group operates as a live entertainment company. The company is headquartered in Englewood, Colorado.
 
2024 EPS Estimate: $1.40
2025 EPS Estimate: ($1.86)

Current Stock Price
$37.16
Consensus Rating
Buy
Ratings Breakdown
1 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings.
Consensus Price Target
N/A



#16 - Brookfield Renewable (NYSE:BEPC)

Brookfield Renewable logoBrookfield Renewable Corporation owns and operates a portfolio of renewable power and sustainable solution assets primarily in the United States, Europe, Colombia, and Brazil. It operates hydroelectric, wind, and solar power plants with an installed capacity of approximately 12,857 megawatts. The company was incorporated in 2019 and is headquartered in New York, New York.
 
Trailing Twelve Months EPS: ($0.32)
2024 EPS Estimate: ($1.11)
2025 EPS Estimate: ($1.13)

Current Stock Price
$24.91
Dividend Yield
5.40%
Consensus Rating
Buy
Ratings Breakdown
2 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings.
Consensus Price Target
$34.00 (36.5% Upside)



#17 - Viasat (NASDAQ:VSAT)

Viasat logoViasat, Inc provides broadband and communications products and services worldwide. The company's Satellite Services segment offers satellite-based fixed broadband services, including broadband internet access and voice over internet protocol services to consumers and businesses; in-flight entertainment and aviation software services to commercial airlines and private business jets; satellite-based connectivity services; mobile broadband services, including satellite-based internet services to energy offshore vessels, cruise ships, consumer ferries, and yachts; and energy services, which include ultra-secure solutions IP connectivity, bandwidth-optimized over-the-top applications, industrial internet-of-things big data enablement, and industry-leading machine learning analytics. Read More 
 
Trailing Twelve Months EPS: $7.58
2024 EPS Estimate: ($1.43)
2025 EPS Estimate: ($1.87)

Current Stock Price
$20.76
P/E Ratio
2.7
Consensus Rating
Hold
Ratings Breakdown
2 Buy Ratings, 4 Hold Ratings, 0 Sell Ratings.
Consensus Price Target
$40.17 (93.5% Upside)



#18 - Sprout Social (NASDAQ:SPT)

Sprout Social logoSprout Social, Inc designs, develops, and operates a web-based social media management platform in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It provides cloud software that brings together social messaging, data, and workflows in a unified system of record, intelligence, and action. Read More 
 
Trailing Twelve Months EPS: ($1.20)
2024 EPS Estimate: ($1.24)
2025 EPS Estimate: ($1.39)

Current Stock Price
$62.66
Consensus Rating
Moderate Buy
Ratings Breakdown
10 Buy Ratings, 1 Hold Ratings, 0 Sell Ratings.
Consensus Price Target
$69.62 (11.1% Upside)



#19 - DISH Network (NASDAQ:DISH)

DISH Network logoDISH Network Corporation, together with its subsidiaries, provides pay-TV services in the United States. The company operates in two segments, Pay-TV and Wireless. It offers video services under the DISH TV brand; and programming packages that include programming through national broadcast networks, local broadcast networks, and national and regional cable networks, as well as regional and specialty sports channels, premium movie channels, and Latino and international programming packages. Read More 
 
Trailing Twelve Months EPS: $1.87
2024 EPS Estimate: $0.46
2025 EPS Estimate: ($0.17)

Current Stock Price
$5.77
P/E Ratio
3.1
Consensus Rating
Hold
Ratings Breakdown
3 Buy Ratings, 8 Hold Ratings, 2 Sell Ratings.
Consensus Price Target
$10.27 (78.0% Upside)



#20 - Recursion Pharmaceuticals (NASDAQ:RXRX)

Recursion Pharmaceuticals logoRecursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 1b/2 clinical trial to treat AXIN1 or APC mutant cancers. Read More 
 
Trailing Twelve Months EPS: ($1.46)
2024 EPS Estimate: ($1.68)
2025 EPS Estimate: ($1.92)

Current Stock Price
$13.91
Consensus Rating
Hold
Ratings Breakdown
1 Buy Ratings, 3 Hold Ratings, 0 Sell Ratings.
Consensus Price Target
$12.00 (13.7% Downside)



More Investing Slideshows: